We are live on ! Find out more
EW icon

Edwards Lifesciences

556 hedge funds and large institutions have $11.7B invested in Edwards Lifesciences in 2014 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 193 increasing their positions, 182 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 1015 (+5)

12% more funds holding

Funds holding: 496556 (+60)

6% more repeat investments, than reductions

Existing positions increased: 193 | Existing positions reduced: 182

5% less capital invested

Capital invested by funds: $12.4B → $11.7B (-$651M)

7.78% less ownership

Funds ownership: 523.44%515.66% (-7.8%)

15% less call options, than puts

Call options by funds: $44.3M | Put options by funds: $52.1M

Holders
556
Holders Change
+60
Holders Change %
+12.1%
% of All Funds
14.83%
Holding in Top 10
15
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+50%
% of All Funds
0.4%
New
97
Increased
193
Reduced
182
Closed
31
Calls
$44.3M
Puts
$52.1M
Net Calls
-$7.8M
Net Calls Change
-$17.2M
Name Holding Trade Value Shares
Change
Change in
Stake
EHC
226
Everett Harris & Co
California
$3.44M
TCM
227
Twin Capital Management
Pennsylvania
$3.42M +$257K +12,780 +9%
SRC
228
Stone Run Capital
New York
$3.39M
Financial Engines Advisors
229
Financial Engines Advisors
California
$3.32M +$14.5K +720 +0.5%
IRF
230
IBM Retirement Fund
New York
$3.31M +$140K +6,972 +5%
EIM
231
ExxonMobil Investment Management
Texas
$3.21M -$92K -4,578 -3%
FAF
232
Fjarde Ap-fonden
Sweden
$3.2M -$144K -7,182 -5%
WCM
233
Washington Capital Management
Washington
$3.17M
CCS
234
Crosspoint Capital Strategies
California
$3.17M +$3M +149,106 New
VKH
235
Virtu KCG Holdings
New York
$3.13M +$1.5M +74,580 +102%
GIA
236
Gargoyle Investment Advisor
New Jersey
$3.07M +$1.1M +54,960 +61%
SIM
237
Spark Investment Management
New York
$3.03M +$832K +41,400 +41%
CCM
238
Cupps Capital Management
Illinois
$2.9M +$797K +39,666 +41%
CIBC World Market
239
CIBC World Market
Ontario, Canada
$2.84M +$2.68M +133,596 New
OPERF
240
Oregon Public Employees Retirement Fund
Oregon
$2.73M +$726K +36,156 +39%
B
241
Barings
North Carolina
$2.64M +$163K +8,100 +7%
DekaBank Deutsche Girozentrale
242
DekaBank Deutsche Girozentrale
Germany
$2.63M +$723K +36,000 +42%
LP
243
LMR Partners
United Kingdom
$2.55M +$2.03M +101,076 +532%
GS
244
GAM Systematic
United Kingdom
$2.52M +$2.39M +118,776 New
MAA
245
Managed Account Advisors
New Jersey
$2.5M +$1.79M +89,286 +312%
COPPSERS
246
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$2.49M +$8.8K +438 +0.4%
FM
247
Forward Management
California
$2.48M +$157K +7,800 +5%
RB
248
Rodgers Brothers
Pennsylvania
$2.43M -$139K -6,942 -6%
MC
249
Menta Capital
California
$2.42M -$574K -28,560 -20%
RPAM
250
Rhenman & Partners Asset Management
Sweden
$2.42M -$121K -6,000 -5%

EW Hedge Fund Activity: Q4 2014 in Review

556 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q4 2014, worth a combined $11.7B — down 5.3% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new EW positions and 31 closed out — a net gain of 66 holders — while 193 added to existing stakes and 182 trimmed.

The largest buyer was AQR Capital Management, adding an estimated $85M. The largest seller was Capital Research Global Investors, cutting an estimated $232M.

  • 556 institutional investors held Edwards Lifesciences (EW) as of Q4 2014, up from 496 in Q3 2014.
  • Funds reported $11.7B of Edwards Lifesciences stock for Q4 2014, down 5.3% quarter-over-quarter.
  • 97 funds opened new Edwards Lifesciences positions in Q4 2014 and 31 closed out, a net change of +66 holders.
  • The largest Edwards Lifesciences buyer in Q4 2014 was AQR Capital Management, an estimated $85M added.
  • The largest Edwards Lifesciences seller in Q4 2014 was Capital Research Global Investors, an estimated $232M sold.

Based on aggregated 13F filings for Q4 2014.